NFKB1 and B-cell chronic lymphocytic leukemia: Besides the ABC-DLBCL, Ibrutinib demonstrated activity in preclinical models of CLL, where it was shown to abrogate downstream survival pathways including ERK1/2, PI3K and NF-κB, providing solid and significant support for the development of Ibrutinib as a therapeutic agent across a variety of B-cell malignancies [22].